rmdopen.bmj2d
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...
rmdopen.bmj11d
Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study
Background Although genome-wide association studies (GWASs) have identified more than 100 loci associated with rheumatoid arthritis (RA) susceptibility, the causal genes and biological mechanisms ...
rmdopen.bmj8d
Impact of filgotinib on pain control in the phase 3 FINCH studies
Present affiliation The present affiliation of Shangbang Rao is: Candel Therapeutics, Needham, MA, USA Present affiliation The present affiliation of Pieter-Jan Stiers is: AgomAb Therapeutics, Ghent, ...
rmdopen.bmj4d
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...
rmdopen.bmj5d
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...
rmdopen.bmj8d
Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives
The therapeutic window of opportunity in rheumatoid arthritis (RA) is often referred to. However, some have questioned whether such a period, in which the disease is more susceptible to ...
rmdopen.bmj11d
Treatment of complex regional pain syndrome type I with bisphosphonates
Complex regional pain syndrome type I (CRPS-I) is a common and disabling disorder affecting a peripheral limb, usually developing after a trauma to an extremity. CRPS-I is characterised by presence of ...
rmdopen.bmj10d
Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
Objectives This study assessed the psychometric properties of the fatigue numeric rating scale (NRS) and sought to establish values for clinically meaningful change (responder definition). Methods ...
rmdopen.bmj24d
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide
The EULAR Sjögren's syndrome (SS) disease activity index (ESSDAI) is a systemic disease activity index that was designed to measure disease activity in patients with primary SS. With the growing use ...
rmdopen.bmj20d
Cost assessment of health interventions and diseases
3 Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, and the CAPHRI Research Institute Maastricht University, Maastricht, Netherlands 4 Patient Research ...
rmdopen.bmj23d
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
Immunomodulatory therapy for rheumatoid arthritis (RA) carries risk for infectious complications. Understanding the risks of different therapeutic options is essential for making treatment decisions ...
rmdopen.bmj23d
Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET
Correspondence to Dr Conny van der Laken; j.vanderlaken{at}amsterdamumc.nl Conclusion Quantitative macrophage PET assessment of feet joints, together with DAS44, after 2 weeks of COBRA light treatment ...